AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

Common respiratory infections like COVID and the flu could awaken dormant breast cancer cells in the lungs and lead to ...

A digital asthma self-management program improves asthma control in adults, with greater benefits observed in non-African ...

The pharmaceutical giant said second-quarter revenue increased to $14.46 billion from $12.94 billion. U.S. revenue was up 13% ...

Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.

Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” second-quarter 2025 investor ...

The UK’s largest listed companies are turning their heads towards the glimmer of the Nasdaq after growing impatient ...

Pharmaceutical stocks are some of the biggest in the FTSE 100. The sector is threatened by tariffs, but some have posted encouraging results regardless.

AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 billion in manufacturing.

In terms of its transformative effect, AI is doing for healthcare what electricity did for the industry. According to Fortune ...

Speaking from Astra's offices in New York, Sir Pascal Soriot (pictured) said it was 'global', but it was 'very much rooted ...